Biogen (BIIB) Tops Q1 EPS by 24c; reaffirms guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $197.19 -1.26%
EPS Growth %: -41.3%
Financial Fact:
Income before income tax expense: 1.37B
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: -41.3%
Financial Fact:
Income before income tax expense: 1.37B
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q1 EPS of $3.67, $0.24 better than the analyst estimate of $3.43. Revenue for the quarter came in at $2.29 billion versus the consensus estimate of $2.31 billion.
GUIDANCE:
Biogen sees FY2024 EPS of $15.00-$16.00, versus the consensus of $15.49.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Worthington Enterprises raises dividend 5%, adds board member
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
